Related Experiment Video

Updated: May 4, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.6K

Gefitinib and non-small cell lunt cancer

    Prescrire International
    |January 16, 2014
    PubMed

    Insights

    Gefitinib does not improve overall survival compared to chemotherapy. This drug causes severe side effects due to epithelial toxicity.

    Area of Science:

    • Oncology
    • Pharmacology

    Background:

    • Gefitinib is a targeted therapy used in cancer treatment.
    • Chemotherapy remains a standard treatment for many cancers.

    Purpose of the Study:

    • To evaluate the efficacy and safety of gefitinib compared to chemotherapy.
    • To analyze overall survival and adverse events associated with gefitinib.

    Main Methods:

    • Meta-analysis of three systematic reviews.
    • Comparison of gefitinib versus first- or second-line chemotherapy.

    Main Results:

    • Gefitinib did not prolong overall survival compared to chemotherapy.
    • Gefitinib was associated with severe adverse effects, primarily epithelial toxicity.

    Conclusions:

    • Gefitinib is not superior to chemotherapy in terms of overall survival.
    • The epithelial toxicity of gefitinib necessitates careful consideration of its use and management of side effects.

    More Related Videos

    Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

    Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

    Published on: August 11, 2017

    8.0K
    A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

    A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

    Published on: April 6, 2016

    9.5K

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    7.0K
    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
    4.9K
    Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

    Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

    Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
    TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
    689